Amyotrophic Lateral Sclerosis Market Insight, Epidemiology and Market Forecast -2030

This report can be delivered to the clients within 24 Hours

DelveInsight’s ‘Amyotropic Lateral Sclerosis (ALS) - Market Insights, Epidemiology and Market Forecast– 2030’ report delivers an in-depth understanding of the ALS , historical and forecasted epidemiology as well as the ALS market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The ALS market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM ALS market size from 2017 to 2030. The report also covers current ALS treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2030

Amyotropic Lateral Sclerosis (ALS) Disease Understanding and Treatment Algorithm

Amyotropic Lateral Sclerosis (ALS) Overview

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a group of rare neurological diseases that mainly involve the nerve cells (neurons) responsible for controlling voluntary muscle movement. The disease is progressive, meaning the symptoms get worse over time. In ALS, both the upper motor neurons and the lower motor neurons degenerate or die and stop sending messages to the muscles. Unable to function, the muscles gradually weaken, start to twitch (called fasciculations), and waste away (atrophy). Eventually, the brain loses its ability to initiate and control voluntary movements. The cause of ALS is not known, and it is not yet known why ALS strikes some people and not others. However, evidence from scientific studies suggests that both genetics and environment play a role in the development of ALS.

In ALS, both the upper motor neurons and the lower motor neurons degenerate or die and stop sending messages to the muscles. Unable to function, the muscles gradually weaken, start to twitch (called fasciculations), and waste away (atrophy). Eventually, the brain loses its ability to initiate and control voluntary movements. The cause of ALS is not known, and it is not yet known why ALS strikes some people and not others. However, evidence from scientific studies suggests that both genetics and environment play a role in the development of ALS.

ALS can affect any of the body’s muscles, which is why it affects each person differently. In addition, ALS progresses at different rates in different people. For some, it advances quickly, and in others, the disease shows a much slower pace. Common symptoms include painless, progressive muscle weakness. The first thing a person might notice is tripping more often, or dropping things because of the weakness. Slurred speech, difficulty swallowing, and trouble breathing can occur.

ALS can be either sporadic or genetic. The sporadic type is the most common. It accounts for 90–95% of all cases of ALS. The sporadic type can affect anyone. The genetic or familial type is rarer and accounts for 5–10% of cases of ALS. The terms familial and genetic mean that this type of ALS is inherited. In families who have genetic ALS, there is an up to 50% chance that each child will inherit the gene and develop the disease.

Amyotropic Lateral Sclerosis (ALS) Diagnosis

No one test can provide a definitive diagnosis of ALS. ALS is primarily diagnosed based on a detailed history of the symptoms and signs observed by a physician during physical examination along with a series of tests to rule out other mimicking diseases. However, the presence of upper and lower motor neuron symptoms strongly suggests the presence of the disease. Tests that may help diagnose ALS are electromyography (EMG), nerve conduction study (NCS), magnetic resonance imaging (MRI). Further tests to rule out other conditions may include blood and urine tests and a muscle biopsy. Medical problems that can produce similar symptoms to ALS, such as HIV, Lyme disease, multiple sclerosis (MS), the poliovirus, and the West Nile virus (WNV), should be considered when making a diagnosis.

Amyotropic Lateral Sclerosis (ALS) Treatment

There is no cure for ALS, so treatment aims to alleviate symptoms, prevent unnecessary complications, and slow the rate of disease progression. Medical interventions and technology have vastly improved the quality of life for people with ALS by assisting with breathing, nutrition, mobility, and communication. Proper management of symptoms and proactive use of medical interventions and equipment can make a positive difference in day-to-day living and potentially may lengthen life.

The cornerstone of disease management for ALS patients remains multidisciplinary care, which has a positive effect on patient satisfaction and outcome. Several discomforting symptoms of ALS can be managed by symptomatic treatment options, including pharmacological and non?pharmacological interventions. For instance, spasticity can be treated with baclofen, tizanidine, cannabinoids, and muscle stretching, and sialorrhea can be treated with anticholinergic medications (amitriptyline, glycopyrronium bromide and oxybutynin) and botulin toxin injections into the salivatory glands. Muscle cramps may respond to magnesium supplements, quinine sulfate, gabapentin, or carbamazepine. Selective serotonin reuptake inhibitors, amitriptyline, benzodiazepines, and dextromethorphan hydrobromide/quinidine sulfate, can be used in the case of emotional liability. Dietary changes can improve nutrition, and a gastrostomy tube is an option if the caloric intake is insufficient or when swallowing becomes hazardous. Speech therapy is frequently necessary, and assisted communication (customized software) can also be used. Non?invasive ventilation is the preferred life?prolonging treatment for respiratory insufficiency.

Amyotropic Lateral Sclerosis (ALS) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Population of Amyotropic Lateral Sclerosis (ALS), Diagnosed Prevalent Population of Amyotropic Lateral Sclerosis (ALS), Gender-specific Distribution of Amyotropic Lateral Sclerosis (ALS), Type-specific Distribution of Amyotropic Lateral Sclerosis (ALS), Mutation-specific Distribution of Amyotropic Lateral Sclerosis (ALS), Site of Onset of Amyotropic Lateral Sclerosis (ALS) and Age-specific Distribution of ALS in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Key Findings

This section provides glimpse of the ALS epidemiology in the 7MM.

• The prevalent population of ALS in the seven major markets was found to be 70,456 in 2017.
• The diagnosed prevalent cases of ALS, in the United States, were found to be 45,796 in 2017 and 48,112 in 2020.
• In the United States, the sporadic and familial ALS cases were 16,015 and 1,779, respectively, in 2017.
• In the United States, the number of males and females with ALS were 11,482 and 7,341, respectively, in 2020.
• ALS can be divided into C9ORF72, SOD1, others mutations (TARDBP, FUS, OPTN, ANG, etc.), and non-mutated/unidentified mutation based on the types of mutations causing the condition. In the United States, the number of cases of C9ORF72, SOD1, others mutations (TARDBP, FUS, OPTN, ANG, etc.), and non-mutated/unidentified mutation was 5,783, 2,847, 1,424 and 7,741, respectively, in 2017.
• In the United States, the most diagnosed site of onset of ALS was limb with 8,897 cases, followed by bulbar and cervical with 4,449 and 2,491 cases, and other uncertain regions accounted for 1,957 cases in 2017.
• Age-specific data of ALS suggests that it is more prevalent among the 60–69 age group. In the United States, the maximum number of cases of ALS was observed in the age group of 60–69 with 5,623 cases in 2017, while the lowest number of cases were found in the age group <20, with 94 cases in 2017.However, in Japan 70+ age group pool had more diagnosed prevalent cases as there is higher geriatric population in the country.
• In the EU5 countries, the diagnosed prevalence of ALS was found to be maximum in Germany with 4,806 cases, followed by the France with 3,923 cases in 2017. While, the least number of cases were found in Spain, with 2,735 cases in 2017.
• In Japan, the diagnosed prevalence of ALS was found to be 9,580 in 2020.

Country-wise Amyotropic Lateral Sclerosis (ALS) Epidemiology

The epidemiology segment also provides the Amyotropic Lateral Sclerosis (ALS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Amyotropic Lateral Sclerosis (ALS) Drug Chapters

The drug chapter segment of the Amyotropic Lateral Sclerosis (ALS) report encloses the detailed analysis of Amyotropic Lateral Sclerosis (ALS) marketed drugs and mid and late stage pipeline drugs. It also helps to understand the Amyotropic Lateral Sclerosis (ALS) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

Amyotropic Lateral Sclerosis (ALS) Marketed Drugs

Radicava (edaravone injection): Mitsubishi Tanabe Pharma Corporation

Radicava is a product of Mitsubishi Tanabe Pharma that contains the active substance edaravone. It is a novel neuroprotective agent that slows down the progression of ALS. It is worth noting that Radicava is the second drug to be approved for the treatment of ALS after more than two decades from the first US FDA approval of riluzole. The mechanism by which Radicava exerts its therapeutic effect in patients with ALS is unknown however it is believed to have shown anti-oxidant properties.

Product details in the report…

Rilutek (Riluzole): Sanofi/Covis

Riluzole was the first drug ever that got approved for the treatment of ALS. Riluzole is in a class of medications called benzothiazoles. The mechanism of action of riluzole in the nervous system is complex. However, it works by changing the activity of certain natural substances in the body that affect nerves and muscles. In the United States, this gold standard therapy of ALS is sold by Covis Pharma and Sanofi holds the ex-U.S. rights to the drug.

Product details in the report…

Exservan (Riluzole oral film): Aquestive Therapeutics

Exservan, formerly known as AQST-117 is an oral Riluzole film used to treat ALS. Exservan consists of a thin film that is placed on the tongue, utilizes the company’s “PharmFilm” technology. The dissolving oral film can be taken twice daily without water, making it easier for patients who have difficulty swallowing pills or liquids. Exservan offers an easy alternative to tablets, liquids, or other traditional forms of medication as it can be taken without water or the need to use swallowing muscles. After receiving a regulatory nod from the US FDA, Aquestive Therapeutics is in the EMA approval process for Exservan.

Product details in the report…

Nuedexta (dextromethorphan hydrobromide/quinidine sulfate): Avanir Pharmaceuticals

Nuedexta a combination product of Avanir Pharmaceuticals is the only approved medication that has proven to be effective in lowering down the Pseudobulbar Affect (PBA). This condition causes involuntary, sudden, and frequent episodes of crying and/or laughing in people living with certain neurologic conditions such as ALS or brain injury. Clinical findings of this candidate have shown that it has significantly reduced around 82% of the PBA episodes in a time of 12 weeks. It is an innovative combination of two components; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan concentrations. Nuedexta acts on sigma-1 and NMDA receptors in the brain, although the mechanism by which Nuedexta exerts therapeutic effects in patients with PBA is unknown.

Product details in the report…

Tiglutik (riluzole): ITF Pharma

Tiglutik (riluzole) oral suspension is indicated for the treatment of ALS. Tiglutik is the first and only easy-to-swallow thickened riluzole liquid for ALS and is administered twice daily via an oral syringe. This candidate is designed to tackle the issues of disease-related dysphagia in ALS. In clinical studies, the most common side effects of Tiglutik were oral hypoesthesia, asthenia, nausea, decreased lung function, hypertension, and abdominal pain. These are not all of the possible side effects that a patient may experience with Tiglutik. While riluzole's mechanism of action is not fully understood, in clinical studies it has been shown repeatedly to modulate glutamate neurotransmission by inhibiting both glutamate release and postsynaptic glutamate receptor signaling.

Product details in the report…

Amyotropic Lateral Sclerosis (ALS) Emerging Drugs

Arimoclomol: Orphazyme

Arimoclomol is an investigational drug candidate of Orphazyme that amplifies the production of Heat-Shock Proteins (HSPs). HSPs can rescue defective misfolded proteins, clear protein aggregates, and improve the function of lysosomes. Arimoclomol is designed to selectively amplify the natural role of endogenous HSPs, protecting the cell against toxicity caused by protein misfolding, aggregation, and lysosomal dysfunction. Arimoclomol has been shown to increase the production of cell-protective HSPs, but only in physiologically stressed cells such as those impacted by the disease. This increase in the production of naturally occurring HSPs inside the cells reduces protein misfolding and aggregation and improves lysosomal function (the cells’ recycling system). Arimoclomol is administered orally or nasogastrically and crosses the blood–brain barrier

Product details in the report…

Tofersen (BIIB067): Biogen

Tofersen (formerly IONIS-SOD1Rx), also known as BIIB067, is an antisense drug designed to reduce the production of SOD1, which is the best understood genetic cause of familial ALS. It works by binding to SOD1 mRNA, allowing for its degradation by RNase-H and reducing SOD1 protein production. This is thought to decrease the toxicity of mutant SOD1 and potentially provide therapeutic benefit through improved survival and function to people with ALS with SOD1 mutations.

Product details in the report…

Levosimendan: Orion Pharma

Levosimendan (marketed as Simdax) is an inodilator that has been used to treat acute heart failure since 2000 and is approved in nearly 60 countries worldwide. The drug was discovered in Orion in the 1990s. It works by increasing calcium sensitivity in both heart and skeletal muscle fibers, potentially improving their function. The effects of levosimendan on skeletal muscle suggested a possible clinical value of levosimendan in treating patients with ALS. Hence, Orion initiated a clinical development program to study the effects of the drug on respiratory function in patients with ALS, and the results of Phase II clinical trial (LEVALS) were promising.

Product details in the report…

Masitinib: AB Science

Masitinib (AB1010) is an orally administered tyrosine kinase inhibitor. It modulates mast cells and macrophages’ activity–important cells for immunity—by targeting a limited number of kinases without inhibiting, at therapeutic doses, kinases associated with known toxicities. Based on its unique mechanism of action, masitinib can be developed in many conditions in oncology, inflammatory diseases, and certain diseases of the central nervous system.

Product details in the report…

Tirasemtiv: Cytokinetics

Tirasemtiv (formerly CK-2017357) is a fast skeletal muscle troponin activator (FSTA) that selectively activates the fast skeletal muscle troponin complex by increasing its sensitivity to calcium. In preclinical studies and early clinical trials, the drug has demonstrated increases in skeletal muscle force in response to neuronal input and delays in the onset and reductions in the degree of muscle fatigue. It has been granted orphan drug designation and fast track status by the US FDA and orphan medicinal product designation by the EMA for the potential treatment of ALS.

Verdiperstat: Biohaven Pharmaceuticals

Verdiperstat (formerly named AZD3241) is a first-in-class, potent, selective, brain-permeable, irreversible myeloperoxidase (MPO) enzyme inhibitor. MPO is believed to play an essential role in multiple neurodegenerative diseases because it increases oxidative stress and inflammation levels in the nervous system. Inhibiting MPO is anticipated to ameliorate these pathological mechanisms, which are strongly implicated in ALS’s onset and progression.

Product details in the report…

Amyotropic Lateral Sclerosis (ALS) Market Outlook

Currently, there is no cure for ALS and no effective treatment to halt or reverse, the progression of the disease. The treatment landscape of ALS includes multidisciplinary care, such as physical therapy, speech therapy, dietary counselling, heat or whirlpool therapy and others. Moreover, there are four drugs approved by the US FDA to treat ALS, namely Riluzole, Nuedexta, Radicava, and Tiglutik. Medications are also prescribed to help manage symptoms of ALS, including pain, muscle cramps, stiffness, excess saliva and phlegm, and the pseudobulbar affect (involuntary or uncontrollable episodes of crying and/or laughing, or other emotional displays). Drugs also are available to help individuals with pain, depression, sleep disturbances, and constipation.

Pain relievers or muscle relaxants such as baclofen (Gablofen, Kemstro, Lioresal) or diazepam (Diastat, Valium) can help ease cramps. Often conservative treatment is used with physical therapy, stretching, and proactive management of pressure sores. Opioids are commonly used for pain relief in people with ALS. Although opiates have a side effect of respiratory depression at high doses, at lower doses they may decrease air hunger without much effect on overall lifespan. Evidence-based treatments for depression or anxiety in people with ALS specifically are lacking, and mood changes are treated with standard treatments, including selective serotonin reuptake inhibitors (SSRIs). Tricyclic antidepressants (TCAs) are often also used.

Most treatments for ALS involve managing the symptoms of the disease as it worsens. Physical therapy and special equipment can enhance an individual’s independence and safety throughout ALS. Gentle, low-impact aerobic exercise such as walking, swimming, and stationary bicycling can strengthen unaffected muscles, improve cardiovascular health, and help people fight fatigue and depression. Occupational therapists can suggest devices such as ramps, braces, walkers, and wheelchairs that help individuals conserve energy and remain mobile. Speech therapy and communication training are also given to maintain verbal communication skills as possible. Communication training also includes non-verbal techniques. Some people with ALS may choose to use voice banking while they are still able to speak as a process of storing their voice for future use in computer-based speech synthesizers. Further, nutritional counseling is to promote good nutrition and recommend other dietary options when swallowing becomes difficult.

Additionally, there are also a variety of tools and mechanical devices that can help with ALS such as splints, reach extenders, and grab-bars. Breathing support such as noninvasive ventilation (NIV) is also used during shortness of breath during physical activity and difficulty breathing at night or when lying down. NIV refers to breathing support that is usually delivered through a mask over the nose and/or mouth. As the disease progresses and muscles weaken further, individuals may consider forms of mechanical ventilation (respirators) in which a machine inflates and deflates the lungs.

Key Findings

This section includes a glimpse of the ALS 7MM market.

• The market size of ALS in the seven major markets was estimated to be USD 233 Million in 2017.
• The United States accounts for the largest market size of ALS in comparison to EU5 (the United Kingdom, Germany, France, Italy, and Spain) and Japan.
• The United States accounted for more than half (64%) of the market share in the 7MM.
• Among the EU5 countries, Germany had the highest market size with USD 11 Million in 2017, while Spain had the smallest market size of ALS with USD 6 Million in 2017, which is expected to rise during the study period 2017–2030.
• The Japan ALS market accounted for USD 41 Million in 2017.

The United States Market Outlook

This section provides the total Amyotropic Lateral Sclerosis (ALS) market size and market size by therapies in the United States.

EU-5 Market Outlook

The total Amyotropic Lateral Sclerosis (ALS) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Amyotropic Lateral Sclerosis (ALS) market size and market size by therapies in Japan are provided.

Amyotropic Lateral Sclerosis (ALS) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Amyotropic Lateral Sclerosis (ALS) market or expected to get launched in the market during the study period 2017–2030. The analysis covers Amyotropic Lateral Sclerosis (ALS) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Amyotropic Lateral Sclerosis (ALS) Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Amyotropic Lateral Sclerosis (ALS) emerging therapies.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Amyotropic Lateral Sclerosis (ALS) market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of Amyotropic Lateral Sclerosis (ALS) , explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
• Comprehensive insight has been provided into the Amyotropic Lateral Sclerosis (ALS) epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for Amyotropic Lateral Sclerosis (ALS) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of Amyotropic Lateral Sclerosis (ALS) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Amyotropic Lateral Sclerosis (ALS) market.

Report Highlights

• In the coming years, ALS market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence ALS R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Delvelnsight analysed gender-specific data of ALS, which suggests that ALS is more prevalent in males than in females.
• Delvelnsight has also analysed mutation-specific data of ALS, mutation-specific data of ALS, which suggests that mutations in the C9ORF72 and SOD1 genes are the most common causes of ALS while mutation in several other genes (TARDBP, FUS, OPTN, ANG,etc.) and non-mutated/unidentified mutations are also involved in the development of ALS.
• Type-specific data of ALS suggests that ALS can be divided into two sub-types, namely, Sporadic and Familial ALS.
• Age-specific data of ALS suggests that prevalence of ALS increase with age, especially after the age of 60–69 years.
• The treatment landscape of ALS includes multidisciplinary care, such as physical therapy, speech therapy, dietary counselling, heat or whirlpool therapy and others. Moreover, there are four drugs approved by the US FDA to treat ALS, namely Riluzole, Nuedexta, Radicava, and Tiglutik.
• Expected Launch of potential therapies, Arimoclomol (Orphazyme), Levosimendan (Orion Pharma), Tirasemtive (Cytokinetics), Verdiperstat (Biohaven Pharmaceuticals), Ibudilast (MediciNova), Masitinib (AB Science), NurOwn (Brainstorm-Cell Therapeutics), AMX0035 (Amylyx Pharmaceuticals), Ranolazine (Gilead Sciences), EPI-589 (PTC Therapeutics), Ezogabine (GlaxoSmithKline), Gold Nanocrystals/CNM-Au8 (Clene Nanomedicine) and others will increase the market size in the coming years, assisted by an increase in diagnosed prevalent population of ALS.

Amyotropic Lateral Sclerosis (ALS) Report Insights

• Patient Population
• Therapeutic Approaches
• Amyotropic Lateral Sclerosis (ALS) Pipeline Analysis
• Amyotropic Lateral Sclerosis (ALS) Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Amyotropic Lateral Sclerosis (ALS) Report Key Strengths

• Eleven Years Forecast
• 7MM Coverage
• Amyotropic Lateral Sclerosis (ALS) Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Amyotropic Lateral Sclerosis (ALS) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions

Market Insights:

• What was the Amyotropic Lateral Sclerosis (ALS) market share (%) distribution in 2017 and how it would look like in 2030?
• What would be the Amyotropic Lateral Sclerosis (ALS) total market size as well as market size by therapies across the 7MM during the forecast period (2020–2030)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest Amyotropic Lateral Sclerosis (ALS) market size during the forecast period (2020–2030)?
• At what CAGR, the Amyotropic Lateral Sclerosis (ALS) market is expected to grow at the 7MM level during the forecast period (2020–2030)?
• What would be the Amyotropic Lateral Sclerosis (ALS) market outlook across the 7MM during the forecast period (2020–2030)?
• What would be the Amyotropic Lateral Sclerosis (ALS) market growth till 2030 and what will be the resultant market size in the year 2030?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of Amyotropic Lateral Sclerosis (ALS) ?
• What is the historical Amyotropic Lateral Sclerosis (ALS) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of Amyotropic Lateral Sclerosis (ALS) at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Amyotropic Lateral Sclerosis (ALS) ?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Amyotropic Lateral Sclerosis (ALS) during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the treatment of Amyotropic Lateral Sclerosis (ALS) along with the approved therapy?
• What are the current treatment guidelines for the treatment of Amyotropic Lateral Sclerosis (ALS) in the US and Europe?
• What are the Amyotropic Lateral Sclerosis (ALS) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Amyotropic Lateral Sclerosis (ALS) ?
• How many therapies are developed by each company for the treatment of Amyotropic Lateral Sclerosis (ALS) ?
• How many emerging therapies are in the mid-stage and late stage of development for the treatment of Amyotropic Lateral Sclerosis (ALS) ?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Amyotropic Lateral Sclerosis (ALS) therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Amyotropic Lateral Sclerosis (ALS) and their status?
• What are the key designations that have been granted for the emerging therapies for Amyotropic Lateral Sclerosis (ALS) ?
• What are the 7MM historical and forecasted market of Amyotropic Lateral Sclerosis (ALS) ?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Amyotropic Lateral Sclerosis (ALS) .
• To understand the future market competition in the Amyotropic Lateral Sclerosis (ALS) market and Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Amyotropic Lateral Sclerosis (ALS) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for Amyotropic Lateral Sclerosis (ALS) market.
• To understand the future market competition in the Amyotropic Lateral Sclerosis (ALS) market.

LIST OF TABLES

Table 1: Summary of ALS, Market, Epidemiology and Key Events (2017–2030)
Table 2: List of differential diagnosis and clinical overlap with ALS
Table 3: Summary table of amyotrophic lateral sclerosis and key differentiating factors with each mimic/variant
Table 4: Diagnostic tests for ALS
Table 5: Revised El Escorial Criteria for ALS
Table 6: Recognized Establishments for ALS
Table 7: Neuroprotective and Symptomatic Treatments for ALS
Table 8: Clinical practice and treatment guidelines for ALS in Japan, the United States, and Europe.
Table 9: Prevalent Population of Amyotrophic Lateral Sclerosis in the 7MM (2017–2030)
Table 10: Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis in the 7MM (2017–2030)
Table 11: Prevalence of Amyotrophic Lateral Sclerosis in the US (2017–2030)
Table 12: Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in the US (2017–2030)
Table 13: Gender-specific Distribution of Amyotrophic Lateral Sclerosis in the US (2017–2030)
Table 14: Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in the US (2017–2030)
Table 15: Type-specific Distribution of Amyotrophic Lateral Sclerosis in the US (2017–2030)
Table 16: Site of onset of Amyotrophic Lateral Sclerosis in the US (2017–2030)
Table 17: Age-specific Distribution of Amyotrophic Lateral Sclerosis in the US (2017–2030)
Table 18: Prevalence of Amyotrophic Lateral Sclerosis in Germany (2017–2030)
Table 19: Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in Germany (2017–2030)
Table 20: Gender-specific Distribution of Amyotrophic Lateral Sclerosis in Germany (2017–2030)
Table 21: Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in Germany (2017–2030)
Table 22: Type-specific Distribution of Amyotrophic Lateral Sclerosis in Germany (2017–2030)
Table 23: Site of onset of Amyotrophic Lateral Sclerosis in Germany (2017–2030)
Table 24: Age-specific Distribution of Amyotrophic Lateral Sclerosis in Germany (2017–2030)
Table 25: Prevalence of Amyotrophic Lateral Sclerosis in France (2017–2030)
Table 26: Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in France (2017–2030)
Table 27: Gender-specific Distribution of Amyotrophic Lateral Sclerosis in France (2017–2030)
Table 28: Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in France (2017–2030)
Table 29: Type-specific Distribution of Amyotrophic Lateral Sclerosis in France (2017–2030)
Table 30: Site of onset of Amyotrophic Lateral Sclerosis in France (2017–2030)
Table 31: Age-specific Distribution of Amyotrophic Lateral Sclerosis in France (2017–2030)
Table 32: Prevalence of Amyotrophic Lateral Sclerosis in Italy (2017–2030)
Table 33: Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in Italy (2017–2030)
Table 34: Gender-specific Distribution of Amyotrophic Lateral Sclerosis in Italy (2017–2030)
Table 35: Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in Italy (2017–2030)
Table 36: Type-specific Distribution of Amyotrophic Lateral Sclerosis in Italy (2017–2030)
Table 37: Site of onset of Amyotrophic Lateral Sclerosis in Italy (2017–2030)
Table 38: Age-specific Distribution of Amyotrophic Lateral Sclerosis in Italy (2017–2030)
Table 39: Prevalence of Amyotrophic Lateral Sclerosis in Spain (2017–2030)
Table 40: Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in Spain (2017–2030)
Table 41: Gender-specific Distribution of Amyotrophic Lateral Sclerosis in Spain (2017–2030)
Table 42: Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in Spain (2017–2030)
Table 43: Type-specific Distribution of Amyotrophic Lateral Sclerosis in Spain (2017–2030)
Table 44: Site of onset of Amyotrophic Lateral Sclerosis in Spain (2017–2030)
Table 45: Age-specific Distribution of Amyotrophic Lateral Sclerosis in Spain (2017–2030)
Table 46: Prevalence of Amyotrophic Lateral Sclerosis in the UK (2017–2030)
Table 47: Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in the UK (2017–2030)
Table 48: Gender-specific Distribution of Amyotrophic Lateral Sclerosis in the UK (2017–2030)
Table 49: Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in the UK (2017–2030)
Table 50: Type-specific Distribution of Amyotrophic Lateral Sclerosis in the UK (2017–2030)
Table 51: Site of onset of Amyotrophic Lateral Sclerosis in the UK (2017–2030)
Table 52: Age-specific Distribution of Amyotrophic Lateral Sclerosis in the UK (2017–2030)
Table 53: Prevalence of Amyotrophic Lateral Sclerosis in Japan (2017–2030)
Table 54: Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in Japan (2017–2030)
Table 55: Gender-specific Distribution of Amyotrophic Lateral Sclerosis in Japan (2017–2030)
Table 56: Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in Japan (2017–2030)
Table 57: Type-specific Distribution of Amyotrophic Lateral Sclerosis in Japan (2017–2030)
Table 58: Site of onset of Amyotrophic Lateral Sclerosis in Japan (2017–2030)
Table 59: Age-specific Distribution of Amyotrophic Lateral Sclerosis in Japan (2017–2030)
Table 60: Comparison of marketed drugs
Table 61: Patent Expiration
Table 62: Patent Expiration
Table 63: Patent Expiration
Table 64: Patent Expiration
Table 65: Comparison of Emerging Drugs
Table 66: Arimoclomol, Clinical Trial Description, 2020
Table 67: Tofersen, Clinical Trial Description, 2020
Table 68: Levosimendan; Clinical Trial Description, 2020
Table 69: NurOwn, Clinical Trial Description, 2020
Table 70: Masitinib; Clinical Trial Description, 2020
Table 71: Ravulizumab; Clinical Trial Description, 2020
Table 72: Tirasemtiv, Clinical Trial Description, 2020
Table 73: Verdiperstat, Clinical Trial Description, 2020
Table 74: MN-166 (Ibudilast); Clinical Trial Description, 2020
Table 75: AMX0035; Clinical Trial Description, 2020
Table 76: Zilucoplan; Clinical Trial Description, 2020
Table 77: CNM-Au8, Clinical Trial Description, 2020
Table 78: ALZT-OP1a (cromolyn); Clinical Trial Description, 2020
Table 79: Reldesemtiv, Clinical Trial Description, 2020
Table 80: RNS60, Clinical Trial Description, 2020
Table 81: ANX005, Clinical Trial Description, 2020
Table 82: PU-AD, Clinical Trial Description, 2020
Table 83: Ezogabine, Clinical Trial Description, 2020
Table 84: Pegcetacoplan, Clinical Trial Description, 2020
Table 85: AT-1501; Clinical Trial Description, 2020
Table 86: Ranolazine; Clinical Trial Description, 2020
Table 87: ILB; Clinical Trial Description, 2020
Table 88: BLZ945, Clinical Trial Description, 2020
Table 89: EPI-589, Clinical Trial Description, 2020
Table 90: BIIB078, Clinical Trial Description, 2020
Table 91: BIIB105, Clinical Trial Description, 2020
Table 92: Seven Major Market Size of ALS in USD Million (2017–2030)
Table 93: Market size of ALS by current therapies in the 7MM, in USD Million (2017–2030)
Table 94: Market size of ALS by emerging therapies in the 7MM, in USD Million (2017–2030)
Table 95: Launch dates of potential emerging drugs
Table 96: Total Market Size of ALS in the United States, in USD Million (2017–2030)
Table 97: Market size of ALS by current therapies in the United States, in USD Million (2017–2030)
Table 98: Market size of ALS by emerging therapies in the United States, in USD Million (2017–2030)
Table 99: Total Market Size of ALS in Germany, in USD Million (2017–2030)
Table 100: Market size of ALS by current therapies in Germany, in USD Million (2017–2030)
Table 101: Market size of ALS by emerging therapies in Germany, in USD Million (2017–2030)
Table 102: Total Market Size of ALS in France, in USD Million (2017–2030)
Table 103: Market size of ALS by current therapies France, in USD Million (2017–2030)
Table 104: Market size of ALS by emerging therapies France, in USD Million (2017–2030)
Table 105: Total Market Size of ALS in Italy, in USD Million (2017–2030)
Table 106: Market size of ALS by current therapies in Italy, in USD Million (2017–2030)
Table 107: Market size of ALS by emerging therapies in Italy, in USD Million (2017–2030)
Table 108: Total Market Size of ALS in Spain, in USD Million (2017–2030)
Table 109: Market size of ALS by current therapies in Spain, in USD Million (2017–2030)
Table 110: Market size of ALS by emerging therapies in Spain, in USD Million (2017–2030)
Table 111: Total Market Size of ALS in the United Kingdom, in USD Million (2017–2030)
Table 112: Market size of ALS by current therapies in the United Kingdom, in USD Million (2017–2030)
Table 113: Market size of ALS by emerging therapies in the United Kingdom, in USD Million (2017–2030)
Table 114: Total Market Size of ALS in Japan, in USD Million (2017–2030)
Table 115: Market size of ALS by current therapies in Japan, in USD Million (2017–2030)
Table 116: Market size of ALS by emerging therapies in Japan, in USD Million (2017–2030)

LIST OF FIGURES

Figure 1: Phenotypic presentations of ALS.
Figure 2: Clustering of ALS genes in pathogenic pathways.
Figure 3: Flowchart for the management of respiratory dysfunction in ALS/ motor neuron disease (MND)
Figure 4: Prevalent Population of Amyotrophic Lateral Sclerosis in the 7MM (2017–2030)
Figure 5: Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis in the 7MM (2017–2030)
Figure 6: Prevalence of Amyotrophic Lateral Sclerosis in the US (2017–2030)
Figure 7: Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in the US (2017–2030)
Figure 8: Gender-specific Distribution of Amyotrophic Lateral Sclerosis in the US (2017–2030)
Figure 9: Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in the US (2017–2030)
Figure 10: Type-specific Distribution of Amyotrophic Lateral Sclerosis in the US (2017–2030)
Figure 11: Site of onset of Amyotrophic Lateral Sclerosis in the US (2017–2030)
Figure 12: Age-specific Distribution of Amyotrophic Lateral Sclerosis in the US (2017–2030)
Figure 13: Prevalence of Amyotrophic Lateral Sclerosis in Germany (2017–2030)
Figure 14: Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in Germany (2017–2030)
Figure 15: Gender-specific Distribution of Amyotrophic Lateral Sclerosis in Germany (2017–2030)
Figure 16: Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in Germany (2017–2030)
Figure 17: Type-specific Distribution of Amyotrophic Lateral Sclerosis in Germany (2017–2030)
Figure 18: Site of onset of Amyotrophic Lateral Sclerosis in Germany (2017–2030)
Figure 19: Age-specific Distribution of Amyotrophic Lateral Sclerosis in Germany (2017–2030)
Figure 20: Prevalence of Amyotrophic Lateral Sclerosis in France (2017–2030)
Figure 21: Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in France (2017–2030)
Figure 22: Gender-specific Distribution of Amyotrophic Lateral Sclerosis in France (2017–2030)
Figure 23: Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in France (2017–2030)
Figure 24: Type-specific Distribution of Amyotrophic Lateral Sclerosis in France (2017–2030)
Figure 25: Site of onset of Amyotrophic Lateral Sclerosis in France (2017–2030)
Figure 26: Age-specific Distribution of Amyotrophic Lateral Sclerosis in France (2017–2030)
Figure 27: Prevalence of Amyotrophic Lateral Sclerosis in Italy (2017–2030)
Figure 28: Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in Italy (2017–2030)
Figure 29: Gender-specific Distribution of Amyotrophic Lateral Sclerosis in Italy (2017–2030)
Figure 30: Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in Italy (2017–2030)
Figure 31: Type-specific Distribution of Amyotrophic Lateral Sclerosis in Italy (2017–2030)
Figure 32: Site of onset of Amyotrophic Lateral Sclerosis in Italy (2017–2030)
Figure 33: Age-specific Distribution of Amyotrophic Lateral Sclerosis in Italy (2017–2030)
Figure 34: Prevalence of Amyotrophic Lateral Sclerosis in Spain (2017–2030)
Figure 35: Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in Spain (2017–2030)
Figure 36: Gender-specific Distribution of Amyotrophic Lateral Sclerosis in Spain (2017–2030)
Figure 37: Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in Spain (2017–2030)
Figure 38: Type-specific Distribution of Amyotrophic Lateral Sclerosis in Spain (2017–2030)
Figure 39: Site of onset of Amyotrophic Lateral Sclerosis in Spain (2017–2030)
Figure 40: Age-specific Distribution of Amyotrophic Lateral Sclerosis in Spain (2017–2030)
Figure 41: Prevalence of Amyotrophic Lateral Sclerosis in the UK (2017–2030)
Figure 42: Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in the UK (2017–2030)
Figure 43: Gender-specific Distribution of Amyotrophic Lateral Sclerosis in the UK (2017–2030)
Figure 44: Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in the UK (2017–2030)
Figure 45: Type-specific Distribution of Amyotrophic Lateral Sclerosis in the UK (2017–2030)
Figure 46: Site of onset of Amyotrophic Lateral Sclerosis in the UK (2017–2030)
Figure 47: Age-specific Distribution of Amyotrophic Lateral Sclerosis in the UK (2017–2030)
Figure 48: Prevalence of Amyotrophic Lateral Sclerosis in Japan (2017–2030)
Figure 49: Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in Japan (2017–2030)
Figure 50: Gender-specific Distribution of Amyotrophic Lateral Sclerosis in Japan (2017–2030)
Figure 51: Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in Japan (2017–2030)
Figure 52: Type-specific Distribution of Amyotrophic Lateral Sclerosis in Japan (2017–2030)
Figure 53: Site of onset of Amyotrophic Lateral Sclerosis in Japan (2017–2030)
Figure 54: Age-specific Distribution of Amyotrophic Lateral Sclerosis in Japan (2017–2030)
Figure 55: Unmet Needs of ALS
Figure 56: Seven Major Market Size of ALS in USD Million (2017–2030)
Figure 57: Market size of ALS by current therapies in the 7MM, in USD Million (2017–2030)
Figure 58: Market size of ALS by emerging therapies in the 7MM, in USD Million (2017–2030)
Figure 59: Total Market Size of ALS in the United States, USD Millions (2017–2030)
Figure 60: Market size of ALS by current therapies in the United States, in USD Million (2017–2030)
Figure 61: Market size of ALS by emerging therapies in the United States, in USD Million (2017–2030)
Figure 62: Total Market Size of ALS in Germany, USD Millions (2017–2030)
Figure 63: Market size of ALS by current therapies in Germany, in USD Million (2017–2030)
Figure 64: Market size of ALS by emerging therapies in Germany, in USD Million (2017–2030)
Figure 65: Total Market Size of ALS in France, USD Millions (2017–2030)
Figure 66: Market size of ALS by current therapies in France, in USD Million (2017–2030)
Figure 67: Market size of ALS by emerging therapies in France, in USD Million (2017–2030)
Figure 68: Total Market Size of ALS in Italy, USD Millions (2017–2030)
Figure 69: Market size of ALS by current therapies in Italy, in USD Million (2017–2030)
Figure 70: Market size of ALS by emerging therapies in Italy, in USD Million (2017–2030)
Figure 71: Total Market Size of ALS in Spain, USD Millions (2017–2030)
Figure 72: Market size of ALS by current therapies in Spain, in USD Million (2017–2030)
Figure 73: Market size of ALS by emerging therapies in Spain, in USD Million (2017–2030)
Figure 74: Total Market Size of ALS in the United Kingdom, USD Millions (2017–2030)
Figure 75: Market size of ALS by current therapies in the United Kingdom, in USD Million (2017–2030)
Figure 76: Market size of ALS by emerging therapies in the United Kingdom, in USD Million (2017–2030)
Figure 77: Total Market Size of ALS in Japan, USD Millions (2017–2030)
Figure 78: Market size of ALS by cu